Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1995 May;63(5):1855–1862. doi: 10.1128/iai.63.5.1855-1862.1995

Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins.

B U von Specht 1, B Knapp 1, G Muth 1, M Bröker 1, K D Hungerer 1, K D Diehl 1, K Massarrat 1, A Seemann 1, H Domdey 1
PMCID: PMC173235  PMID: 7729895

Abstract

Recombinant outer membrane proteins (Oprs) of Pseudomonas aeruginosa were expressed in Escherichia coli as glutathione S-transferase (GST)-linked fusion proteins. GST-linked Oprs F and I (GST-OprF190-350 [GST linked to OprF spanning amino acids 190 to 350] and GST-OprI21-83, respectively) and recombinant hybrid Oprs (GST-OprF190-342-OprI21-83 and GST-OprI21-83-OprF190-350) were isolated and tested for their efficacy as vaccines in immunodeficient mice. GST-OprF-OprI protected the mice against a 975-fold 50% lethal dose of P. aeruginosa. Expression of GST-unfused OprF-OprI failed in E. coli, although this hybrid protein has been expressed without a fusion part in Saccharomyces cerevisiae and used for immunizing rabbits. The immune rabbit sera protected severe combined deficient (SCID) mice against a 1,000-fold 50% lethal dose of P. aeruginosa. Evidence is provided to show that the most C-terminal part of OprF (i.e., amino acids 332 to 350) carries an important protective epitope. Opr-based hybrid proteins may have implications for a clinical vaccine against P. aeruginosa.

Full Text

The Full Text of this article is available as a PDF (371.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amann E., Ochs B., Abel K. J. Tightly regulated tac promoter vectors useful for the expression of unfused and fused proteins in Escherichia coli. Gene. 1988 Sep 30;69(2):301–315. doi: 10.1016/0378-1119(88)90440-4. [DOI] [PubMed] [Google Scholar]
  2. Baldari C., Murray J. A., Ghiara P., Cesareni G., Galeotti C. L. A novel leader peptide which allows efficient secretion of a fragment of human interleukin 1 beta in Saccharomyces cerevisiae. EMBO J. 1987 Jan;6(1):229–234. doi: 10.1002/j.1460-2075.1987.tb04743.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bröker M., Bäuml O., Göttig A., Ochs J., Bodenbenner M., Amann E. Expression of the human blood coagulation protein factor XIIIa in Saccharomyces cerevisiae: dependence of the expression levels from host-vector systems and medium conditions. Appl Microbiol Biotechnol. 1991 Mar;34(6):756–764. doi: 10.1007/BF00169346. [DOI] [PubMed] [Google Scholar]
  4. Bröker M., Noah M., Nassal M., Dietz S., Ochs J., Bäuml O., Waldinger K., Bodenbenner M., Schott U., Grote M. Expression of hepatitis B virus core gene products with specific immunoreactivity for e antigen (HBeAg) in Saccharomyces cerevisiae. J Biotechnol. 1993 Jun;29(3):243–255. doi: 10.1016/0168-1656(93)90056-s. [DOI] [PubMed] [Google Scholar]
  5. Buret A., Dunkley M. L., Pang G., Clancy R. L., Cripps A. W. Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats roles of alveolar macrophages, tumor necrosis factor alpha, and interleukin-1 alpha. Infect Immun. 1994 Dec;62(12):5335–5343. doi: 10.1128/iai.62.12.5335-5343.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cohen J. Naked DNA points way to vaccines. Science. 1993 Mar 19;259(5102):1691–1692. doi: 10.1126/science.8456293. [DOI] [PubMed] [Google Scholar]
  7. Cryz S. J., Jr, Fürer E., Germanier R. Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice. Infect Immun. 1983 Mar;39(3):1067–1071. doi: 10.1128/iai.39.3.1067-1071.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cryz S. J., Jr, Sadoff J. C., Fürer E. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Microb Pathog. 1989 Jan;6(1):75–80. doi: 10.1016/0882-4010(89)90010-7. [DOI] [PubMed] [Google Scholar]
  9. Cryz S. J., Jr, Sadoff J. C., Ohman D., Fürer E. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. J Lab Clin Med. 1988 Jun;111(6):701–707. [PubMed] [Google Scholar]
  10. Duchêne M., Barron C., Schweizer A., von Specht B. U., Domdey H. Pseudomonas aeruginosa outer membrane lipoprotein I gene: molecular cloning, sequence, and expression in Escherichia coli. J Bacteriol. 1989 Aug;171(8):4130–4137. doi: 10.1128/jb.171.8.4130-4137.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Duchêne M., Schweizer A., Lottspeich F., Krauss G., Marget M., Vogel K., von Specht B. U., Domdey H. Sequence and transcriptional start site of the Pseudomonas aeruginosa outer membrane porin protein F gene. J Bacteriol. 1988 Jan;170(1):155–162. doi: 10.1128/jb.170.1.155-162.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Elsheikh L. E., Karlsson K. A., Bergman R., Abaas S. Induction of protective immune response by vaccination against Pseudomonas pneumonia of mink. Zentralbl Veterinarmed B. 1988 May;35(4):256–263. doi: 10.1111/j.1439-0450.1988.tb00495.x. [DOI] [PubMed] [Google Scholar]
  13. Finke M., Duchêne M., Eckhardt A., Domdey H., von Specht B. U. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli. Infect Immun. 1990 Jul;58(7):2241–2244. doi: 10.1128/iai.58.7.2241-2244.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Finke M., Muth G., Reichhelm T., Thoma M., Duchêne M., Hungerer K. D., Domdey H., von Specht B. U. Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies. Infect Immun. 1991 Apr;59(4):1251–1254. doi: 10.1128/iai.59.4.1251-1254.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gallagher P. G., Watanakunakorn C. Pseudomonas bacteremia in a community teaching hospital, 1980-1984. Rev Infect Dis. 1989 Nov-Dec;11(6):846–852. doi: 10.1093/clinids/11.6.846. [DOI] [PubMed] [Google Scholar]
  16. Gilleland H. E., Jr, Parker M. G., Matthews J. M., Berg R. D. Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice. Infect Immun. 1984 Apr;44(1):49–54. doi: 10.1128/iai.44.1.49-54.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Griffith S. J., Nathan C., Selander R. K., Chamberlin W., Gordon S., Kabins S., Weinstein R. A. The epidemiology of Pseudomonas aeruginosa in oncology patients in a general hospital. J Infect Dis. 1989 Dec;160(6):1030–1036. doi: 10.1093/infdis/160.6.1030. [DOI] [PubMed] [Google Scholar]
  18. Hancock R. E. Intrinsic antibiotic resistance of Pseudomonas aeruginosa. J Antimicrob Chemother. 1986 Dec;18(6):653–656. doi: 10.1093/jac/18.6.653. [DOI] [PubMed] [Google Scholar]
  19. Horton R. M., Hunt H. D., Ho S. N., Pullen J. K., Pease L. R. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene. 1989 Apr 15;77(1):61–68. doi: 10.1016/0378-1119(89)90359-4. [DOI] [PubMed] [Google Scholar]
  20. Hughes E. E., Gilleland L. B., Gilleland H. E., Jr Synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa that elicit antibodies reactive with whole cells of heterologous immunotype strains of P. aeruginosa. Infect Immun. 1992 Sep;60(9):3497–3503. doi: 10.1128/iai.60.9.3497-3503.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Jones R. J., Roe E. A., Gupta J. L. Controlled trials of a polyvalent pseudomonas vaccine in burns. Lancet. 1979 Nov 10;2(8150):977–982. doi: 10.1016/s0140-6736(79)92559-5. [DOI] [PubMed] [Google Scholar]
  22. Knapp B., Shaw A., Hundt E., Enders B., Küpper H. A. A histidin alanine rich recombinant antigen protects Aotus monkeys from P. falciparum infection. Behring Inst Mitt. 1988 Apr;(82):349–359. [PubMed] [Google Scholar]
  23. Korvick J. A., Marsh J. W., Starzl T. E., Yu V. L. Pseudomonas aeruginosa bacteremia in patients undergoing liver transplantation: an emerging problem. Surgery. 1991 Jan;109(1):62–68. [PMC free article] [PubMed] [Google Scholar]
  24. Kraehenbuhl J. P., Neutra M. R. Molecular and cellular basis of immune protection of mucosal surfaces. Physiol Rev. 1992 Oct;72(4):853–879. doi: 10.1152/physrev.1992.72.4.853. [DOI] [PubMed] [Google Scholar]
  25. Matthews-Greer J. M., Gilleland H. E., Jr Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model. J Infect Dis. 1987 Jun;155(6):1282–1291. doi: 10.1093/infdis/155.6.1282. [DOI] [PubMed] [Google Scholar]
  26. McManus A. T., Mason A. D., Jr, McManus W. F., Pruitt B. A., Jr Twenty-five year review of Pseudomonas aeruginosa bacteremia in a burn center. Eur J Clin Microbiol. 1985 Apr;4(2):219–223. doi: 10.1007/BF02013601. [DOI] [PubMed] [Google Scholar]
  27. Mutharia L. M., Hancock R. E. Characterization of two surface-localized antigenic sites on porin protein F of Pseudomonas aeruginosa. Can J Microbiol. 1985 Apr;31(4):381–386. doi: 10.1139/m85-073. [DOI] [PubMed] [Google Scholar]
  28. Mutharia L. M., Nicas T. I., Hancock R. E. Outer membrane proteins of Pseudomonas aeruginosa serotype strains. J Infect Dis. 1982 Dec;146(6):770–779. doi: 10.1093/infdis/146.6.770. [DOI] [PubMed] [Google Scholar]
  29. Ozaki L. S., Mattei D., Jendoubi M., Druihle P., Blisnick T., Guillotte M., Puijalon O., Da Silva L. P. Plaque antibody selection: rapid immunological analysis of a large number of recombinant phage clones positive to sera raised against Plasmodium falciparum antigens. J Immunol Methods. 1986 May 22;89(2):213–219. doi: 10.1016/0022-1759(86)90360-1. [DOI] [PubMed] [Google Scholar]
  30. Pruitt B. A., Jr, McManus A. T. Opportunistic infections in severely burned patients. Am J Med. 1984 Mar 30;76(3A):146–154. doi: 10.1016/0002-9343(84)90334-6. [DOI] [PubMed] [Google Scholar]
  31. Roussilhon C., Hundt E., Agrapart M., Stüber W., Knapp B., Dubois P., Ballet J. J. Responses of T cells from sensitized donors to recombinant and synthetic peptides corresponding to sequences of the Plasmodium falciparum SERP antigen. Immunol Lett. 1990 Aug;25(1-3):149–153. doi: 10.1016/0165-2478(90)90107-2. [DOI] [PubMed] [Google Scholar]
  32. Schorr J., Knapp B., Hundt E., Küpper H. A., Amann E. Surface expression of malarial antigens in Salmonella typhimurium: induction of serum antibody response upon oral vaccination of mice. Vaccine. 1991 Sep;9(9):675–681. doi: 10.1016/0264-410x(91)90194-b. [DOI] [PubMed] [Google Scholar]
  33. Smith D. B., Johnson K. S. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene. 1988 Jul 15;67(1):31–40. doi: 10.1016/0378-1119(88)90005-4. [DOI] [PubMed] [Google Scholar]
  34. Toth A., Schödel F., Duchêne M., Massarrat K., Blum B., Schmitt A., Domdey H., von Specht B. U. Protection of immunosuppressed mice against translocation of Pseudomonas aeruginosa from the gut by oral immunization with recombinant Pseudomonas aeruginosa outer membrane protein I expressing Salmonella dublin. Vaccine. 1994 Oct;12(13):1215–1221. doi: 10.1016/0264-410x(94)90246-1. [DOI] [PubMed] [Google Scholar]
  35. von Specht B. U., Strigl G., Ehret W., Brendel W. Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection. Infection. 1987;15(5):408–412. doi: 10.1007/BF01647755. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES